Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Free Cash Flow (2016 - 2025)

Apyx Medical's Free Cash Flow history spans 15 years, with the latest figure at -$2.8 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 11.85% year-over-year to -$2.8 million; the TTM value through Dec 2025 reached -$9.1 million, up 51.44%, while the annual FY2025 figure was -$9.1 million, 51.44% up from the prior year.
  • Free Cash Flow reached -$2.8 million in Q4 2025 per APYX's latest filing, up from -$4.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $3.5 million in Q3 2023 to a low of -$6.4 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$3.3 million, with a median of -$3.9 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: tumbled 3859.32% in 2022, then skyrocketed 163.48% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$118000.0 in 2021, then crashed by 3859.32% to -$4.7 million in 2022, then surged by 50.66% to -$2.3 million in 2023, then plummeted by 38.05% to -$3.2 million in 2024, then grew by 11.85% to -$2.8 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Free Cash Flow are -$2.8 million (Q4 2025), -$4.1 million (Q3 2025), and -$1.5 million (Q2 2025).